Aprea Therapeutics 2025 Q2 Earnings Loss Narrows as Net Income Improves 6.7%

Aprea Therapeutics (APRE) reported its fiscal 2025 Q2 earnings on Aug 12th, 2025, with mixed performance highlighted by a significant decline in revenue but a modest improvement in net loss. The company delivered results that slightly exceeded expectations in loss reduction but missed in top-line performance due to a sharp drop in revenue. Despite the earnings report, the stock's performance post-earnings remains a key concern for investors.

Revenue
Aprea Therapeutics reported total revenue of $118,111 in Q2 2025, a sharp decline of 79.0% from $561,574 in Q2 2024. The decrease was primarily driven by a drop in grant revenue, which was the only revenue source in the quarter. Specifically, grant revenue stood at $118,111, representing the entirety of Aprea’s total revenue for the period. This marks a substantial shift in revenue composition compared to prior periods, with no other segments contributing to the top line.

Earnings/Net Income
Aprea Therapeutics reported a narrowed net loss of $-3.24 million for Q2 2025, representing a 6.7% improvement from the $-3.47 million net loss in Q2 2024. On a per-share basis, the company reported a loss of $-0.53 per share, an 8.6% reduction from the $-0.58 per share loss in the prior-year period. This improvement in losses indicates some level of cost control or efficiency gains, though the company remains unprofitable. The EPS and net income performance can be viewed as marginally positive due to the reduction in losses.

Price Action
The stock price of Aprea Therapeutics edged up 0.59% during the latest trading day, reflecting a short-term positive sentiment. However, this was offset by a 5.03% drop during the most recent full trading week and a 1.73% decline month-to-date, indicating ongoing investor uncertainty and volatility.

Post-Earnings Price Action Review
The performance of Aprea Therapeutics (APRE) following the release of its Q2 2025 earnings report has been disappointing. A historical analysis of the stock over the past three years shows that buying APRE shares immediately after the earnings report and holding for 30 days has yielded negative returns, with the stock declining by 48.6% year-to-date. The reported EPS of -$0.53 and a quarterly loss of $3.24 million contributed to this underperformance. Despite the negative earnings data, analysts maintain a "buy" rating, with a median 12-month price target of $10.50. This contrasts with the stock’s current price of $1.69, suggesting a perceived long-term upside. However, the historical volatility and risk profile may not align with all investors’ risk appetites, particularly given the recent performance.

CEO Commentary
Oren Gilad, Ph.D., President and CEO of Aprea Therapeutics, expressed cautious optimism about the company’s progress in 2025, citing early clinical activity in both lead programs. Notably, in the ACESOT-1051 trial of APR-1051, three patients achieved stable disease, including one with HPV-positive head and neck cancer. For ATRN-119, seven patients showed stable disease, with three experiencing tumor shrinkage at the 550 mg dose. Gilad emphasized the potential of the DDR (DNA Damage Response) assets to deliver meaningful therapeutic advances. The company is focusing on advancing monotherapy and exploring combination strategies to address unmet medical needs, supported by collaborations such as the one with MD Anderson Cancer Center.

Guidance
Aprea Therapeutics expects additional safety and efficacy data from the ACESOT-1051 trial in the second half of 2025, with the completion of the dose-escalation phase projected for the first half of 2026. Similarly, the ABOYA-119 trial is anticipated to yield further data in the second half of 2025, with the recommended Phase 2 dose expected to be identified by mid-2026. The company may explore combination therapies for both APR-1051 and ATRN-119 in future trial arms, contingent upon additional data. Aprea also plans to submit an abstract from the ACESOT-1051 trial to a major oncology conference.

Additional News
Among the non-earnings-related news items in the past three weeks, Aprea Therapeutics did not announce any major mergers and acquisitions or executive changes. However, it did see continued interest from analysts, with the company maintaining its "buy" rating and a 12-month price target of $10.50. This analyst sentiment suggests a belief in long-term potential despite current financial challenges. In addition, the company announced plans to submit an abstract from the ACESOT-1051 trial to a major oncology conference, indicating a strategic move to raise visibility for its clinical programs. The company’s focus on monotherapy and combination strategies remains a key area of interest for stakeholders.